Oppenheimer reiterates its "Outperform" rating on Gilead (GILD -0.2%), saying that the company...

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

Oppenheimer reiterates its "Outperform" rating on Gilead (GILD -0.2%), saying that the company has a number of under-appreciated opportunities related to its HIV combination treatments. Oppenheimer therefore reckons Gilead will generate more money from those medicines than expected.